Literature DB >> 32024723

Expanding U.S. Laboratory Capacity for Neisseria gonorrhoeae Antimicrobial Susceptibility Testing and Whole-Genome Sequencing through the CDC's Antibiotic Resistance Laboratory Network.

Ellen N Kersh1, Cau D Pham2, John R Papp2, Robert Myers3, Richard Steece4, Grace Kubin5, Romesh Gautom6, Evelyn E Nash2, Samera Sharpe2, Kim M Gernert2, Matthew Schmerer2, Brian H Raphael2, Tara Henning7, Anne M Gaynor8, Olusegun Soge9, Karen Schlanger2, Robert D Kirkcaldy2, Sancta B St Cyr2, Elizabeth A Torrone2, Kyle Bernstein2, Hillard Weinstock2.   

Abstract

U.S. gonorrhea rates are rising, and antibiotic-resistant Neisseria gonorrhoeae (AR-Ng) is an urgent public health threat. Since implementation of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturing N. gonorrhoeae in the United States has declined, along with the ability to perform culture-based antimicrobial susceptibility testing (AST). Yet AST is critical for detecting and monitoring AR-Ng. In 2016, the CDC established the Antibiotic Resistance Laboratory Network (AR Lab Network) to shore up the national capacity for detecting several resistance threats including N. gonorrhoeae AR-Ng testing, a subactivity of the CDC's AR Lab Network, is performed in a tiered network of approximately 35 local laboratories, four regional laboratories (state public health laboratories in Maryland, Tennessee, Texas, and Washington), and the CDC's national reference laboratory. Local laboratories receive specimens from approximately 60 clinics associated with the Gonococcal Isolate Surveillance Project (GISP), enhanced GISP (eGISP), and the program Strengthening the U.S. Response to Resistant Gonorrhea (SURRG). They isolate and ship up to 20,000 isolates to regional laboratories for culture-based agar dilution AST with seven antibiotics and for whole-genome sequencing of up to 5,000 isolates. The CDC further examines concerning isolates and monitors genetic AR markers. During 2017 and 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC received 531 and 646 concerning isolates and 605 and 3,159 sequences, respectively. In summary, the AR Lab Network supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection, expanding preexisting notification and analysis systems for resistance detection. Continued, robust AST and genomic capacity can help inform national public health monitoring and intervention.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Neisseria gonorrhoeaezzm321990; antibiotic resistance; antimicrobial resistance; antimicrobial susceptibility testing; gonorrhea; whole-genome sequencing

Mesh:

Substances:

Year:  2020        PMID: 32024723      PMCID: PMC7098741          DOI: 10.1128/JCM.01461-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.

Authors:  Ellen N Kersh; Vanessa Allen; Eric Ransom; Matthew Schmerer; Sancta Cyr; Kim Workowski; Hillard Weinstock; Jean Patel; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

Review 2.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Prediction of Minimum Inhibitory Concentrations of Antimicrobials for Neisseria gonorrhoeae Using Whole-Genome Sequencing.

Authors:  David W Eyre; Daniel Golparian; Magnus Unemo
Journal:  Methods Mol Biol       Date:  2019

4.  Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin.

Authors:  David M Whiley; Amy Jennison; Julie Pearson; Monica M Lahra
Journal:  Lancet Infect Dis       Date:  2018-07       Impact factor: 25.071

5.  Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.

Authors:  Robert D Kirkcaldy; Alesia Harvey; John R Papp; Carlos Del Rio; Olusegun O Soge; King K Holmes; Edward W Hook; Grace Kubin; Stefan Riedel; Jonathan Zenilman; Kevin Pettus; Tremeka Sanders; Samera Sharpe; Elizabeth Torrone
Journal:  MMWR Surveill Summ       Date:  2016-07-15

6.  Future challenges for tracking foodborne diseases: PulseNet, a 20-year-old US surveillance system for foodborne diseases, is expanding both globally and technologically.

Authors:  Efrain M Ribot; Kelley B Hise
Journal:  EMBO Rep       Date:  2016-09-19       Impact factor: 8.807

7.  FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly Available Resource To Support Research, Development, and Regulatory Requirements.

Authors:  Joseph D Lutgring; María-José Machado; Faiza H Benahmed; Patricia Conville; Ribhi M Shawar; Jean Patel; Allison C Brown
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

8.  Comparing the disk-diffusion and agar dilution tests for Neisseria gonorrhoeae antimicrobial susceptibility testing.

Authors:  Hsi Liu; Thomas H Taylor; Kevin Pettus; Steve Johnson; John R Papp; David Trees
Journal:  Antimicrob Resist Infect Control       Date:  2016-11-24       Impact factor: 4.887

9.  Now Is the Time to Implement Whole Genome Sequencing in the Global Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae?

Authors:  Daniel Golparian; Magnus Unemo
Journal:  EClinicalMedicine       Date:  2019-02-18

10.  Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.

Authors:  David W Eyre; Nicholas D Sanderson; Emily Lord; Natasha Regisford-Reimmer; Kevin Chau; Leanne Barker; Markus Morgan; Robert Newnham; Daniel Golparian; Magnus Unemo; Derrick W Crook; Tim Ea Peto; Gwenda Hughes; Michelle J Cole; Helen Fifer; Anne Edwards; Monique I Andersson
Journal:  Euro Surveill       Date:  2018-07
View more
  5 in total

1.  Atypical Mutation in Neisseria gonorrhoeae 23S rRNA Associated with High-Level Azithromycin Resistance.

Authors:  Cau D Pham; Evelyn Nash; Hsi Liu; Matthew W Schmerer; Samera Sharpe; Grace Woods; Brad Roland; Karen Schlanger; Sancta B St Cyr; Jonathan Carlson; Kevin Sellers; Aaron Olsen; Ruth Sanon; Henrietta Hardin; Olusegun O Soge; Brian H Raphael; Ellen N Kersh
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae.

Authors:  Chad S Hewitt; Nader S Abutaleb; Ahmed E M Elhassanny; Alessio Nocentini; Xufeng Cao; Devon P Amos; Molly S Youse; Katrina J Holly; Anil Kumar Marapaka; Weiwei An; Jatinder Kaur; Aaron D Krabill; Ahmed Elkashif; Yehia Elgammal; Amanda L Graboski; Claudiu T Supuran; Mohamed N Seleem; Daniel P Flaherty
Journal:  ACS Infect Dis       Date:  2021-03-25       Impact factor: 5.084

3.  A Multiplex Molecular Assay for Detection of Six penA Codons To Predict Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae.

Authors:  Yamei Li; Lulu Zhang; Leshan Xiu; Di Wang; Yaling Zeng; Feng Wang; Yueping Yin; Junping Peng
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

4.  Surveillance systems to monitor antimicrobial resistance in Neisseria gonorrhoeae: a global, systematic review, 1 January 2012 to 27 September 2020.

Authors:  Nicholas A Medland; Ye Zhang; Praveena Gunaratnam; David A Lewis; Basil Donovan; David M Whiley; Rebecca J Guy; John M Kaldor
Journal:  Euro Surveill       Date:  2022-05

5.  Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data.

Authors:  Kim M Gernert; Sandra Seby; Matthew W Schmerer; Jesse C Thomas; Cau D Pham; Sancta St Cyr; Karen Schlanger; Hillard Weinstock; William M Shafer; Brian H Raphael; Ellen N Kersh
Journal:  Lancet Microbe       Date:  2020-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.